Q4 2017 13F Holders as of 31 Dec 2017
-
Type / Class
-
Equity / Common Shares, No Par Value
-
Shares outstanding
-
28.5M
-
Number of holders
-
32
-
Total 13F shares, excl. options
-
4.68M
-
Shares change
-
+265K
-
Total reported value, excl. options
-
$21.7M
-
Value change
-
+$1.17M
-
Number of buys
-
19
-
Number of sells
-
-4
-
Price
-
$4.65
Significant Holders of Oncocyte Corporation - Common Shares, No Par Value (OCX) as of Q4 2017
34 filings reported holding OCX - Oncocyte Corporation - Common Shares, No Par Value as of Q4 2017.
Oncocyte Corporation - Common Shares, No Par Value (OCX) has 32 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 4.68M shares
of 28.5M outstanding shares and own 16.41% of the company stock.
Largest 10 shareholders include BROADWOOD CAPITAL INC (3.6M shares), Vanguard Group Inc (357K shares), BlackRock Inc. (207K shares), Artal Group S.A. (150K shares), BRIDGEWAY CAPITAL MANAGEMENT INC (145K shares), NORTHERN TRUST CORP (44K shares), Destination Wealth Management (29.7K shares), GEODE CAPITAL MANAGEMENT, LLC (22.2K shares), Bank of New York Mellon Corp (16.8K shares), and MORGAN STANLEY (16K shares).
This table shows the top 32 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.